We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    rtog 1306
Previous Study | Return to List | Next Study

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

This study is currently recruiting participants.
Verified November 2017 by National Cancer Institute (NCI)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01822496
First Posted: April 2, 2013
Last Update Posted: December 8, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
National Cancer Institute (NCI)
  Purpose
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.

Condition Intervention Phase
Stage III Non-Small Cell Lung Cancer AJCC v7 Stage IIIA Non-Small Cell Lung Cancer AJCC v7 Stage IIIB Non-Small Cell Lung Cancer AJCC v7 Radiation: 3-Dimensional Conformal Radiation Therapy Drug: Carboplatin Drug: Cisplatin Drug: Crizotinib Drug: Erlotinib Hydrochloride Drug: Etoposide Radiation: Intensity-Modulated Radiation Therapy Other: Laboratory Biomarker Analysis Drug: Paclitaxel Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Progression-free survival [ Time Frame: Occurrence of local or regional progression, distant metastases, or death from any cause from the time of randomization to the occurrence of one of the failure events, whichever occurs first, assessed up to 12 months ]
    The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.


Secondary Outcome Measures:
  • Deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available [ Time Frame: Baseline ]
    Tumor molecular aberrations identified from deep sequencing of selected kinomes will be correlated with clinical outcomes.

  • Distant progression free survival [ Time Frame: Time from randomization to distant progression or death, whichever occurs first, assessed up to 10 years ]
    Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.

  • Incidence of grade 3-5 adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 [ Time Frame: Up to 10 years ]
    Summarized using frequency table methods.

  • Local-regional progression free survival [ Time Frame: Time from randomization to local-regional progression or death, whichever comes first, assessed up to 10 years ]
    Appropriate methods for competing risks will be applied, specifically cumulative incidence functions for estimation of cumulative cause specific event probabilities with associated testing for differences, and regression methods for cause-specific hazards and subdistribution hazards underlying cumulative incidence functions may be applied accordingly for exploratory purposes.

  • Overall survival [ Time Frame: Time to death from any cause, assessed up to 12 months ]
    The product limit estimator developed by Kaplan and Meier will be used. Their 95% confidence intervals will be estimated. Comparisons between arms will be conducted using a log rank test.

  • Proportion of patients who respond (completely or partially) to each treatment, assessed by the Response Evaluation Criteria in Solid Tumors [ Time Frame: Up to 10 years ]
    Estimated as well as their 95% confidence intervals. Response rate will be tested using Fisher's exact test and using a logistic regression model to incorporate other prognostic covariates.


Estimated Enrollment: 234
Actual Study Start Date: November 4, 2013
Estimated Primary Completion Date: December 31, 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm I (erlotinib hydrochloride, concurrent chemoradiation)
Patients receive erlotinib hydrochloride PO QD for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3-D CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Erlotinib Hydrochloride
Given PO
Other Names:
  • Cp-358,774
  • OSI-774
  • Tarceva
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat
Active Comparator: Arm II (chemoradiation, EGFR TK Mutation Cohort)
Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3-D CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat
Experimental: Arm III (crizotinib, concurrent chemoradiation)
Patients receive crizotinib PO BID for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3-D CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Crizotinib
Given PO
Other Names:
  • MET tyrosine kinase inhibitor PF-02341066
  • PF-02341066
  • PF-2341066
  • Xalkori
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat
Active Comparator: Arm IV (chemoradiation, ALK Tran L Cohort)
Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.
Radiation: 3-Dimensional Conformal Radiation Therapy
Undergo 3-D CRT
Other Names:
  • 3-dimensional radiation therapy
  • 3D CONFORMAL RADIATION THERAPY
  • 3D CRT
  • 3D-CRT
  • Conformal Therapy
  • Radiation Conformal Therapy
Drug: Carboplatin
Given IV
Other Names:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Carbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Paraplatine
  • Platinwas
  • Ribocarbo
Drug: Cisplatin
Given IV
Other Names:
  • Abiplatin
  • Blastolem
  • Briplatin
  • CDDP
  • Cis-diammine-dichloroplatinum
  • Cis-diamminedichloridoplatinum
  • Cis-diamminedichloro Platinum (II)
  • Cis-diamminedichloroplatinum
  • Cis-dichloroammine Platinum (II)
  • Cis-platinous Diamine Dichloride
  • Cis-platinum
  • Cis-platinum II
  • Cis-platinum II Diamine Dichloride
  • Cismaplat
  • Cisplatina
  • Cisplatinum
  • Cisplatyl
  • Citoplatino
  • Citosin
  • Cysplatyna
  • DDP
  • Lederplatin
  • Metaplatin
  • Neoplatin
  • Peyrone's Chloride
  • Peyrone's Salt
  • Placis
  • Plastistil
  • Platamine
  • Platiblastin
  • Platiblastin-S
  • Platinex
  • Platinol
  • Platinol- AQ
  • Platinol-AQ
  • Platinol-AQ VHA Plus
  • Platinoxan
  • Platinum
  • Platinum Diamminodichloride
  • Platiran
  • Platistin
  • Platosin
Drug: Etoposide
Given IV
Other Names:
  • Demethyl Epipodophyllotoxin Ethylidine Glucoside
  • EPEG
  • Lastet
  • Toposar
  • Vepesid
  • VP 16-213
  • VP-16
  • VP-16-213
Radiation: Intensity-Modulated Radiation Therapy
Undergo IMRT
Other Names:
  • IMRT
  • Intensity Modulated RT
  • Intensity-Modulated Radiotherapy
Other: Laboratory Biomarker Analysis
Correlative studies
Drug: Paclitaxel
Given IV
Other Names:
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol
  • Taxol Konzentrat

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess whether patients with unresectable local-regionally advanced non-small cell lung cancer (NSCLC) treated with targeted agents based on molecular characteristics have a longer progression-free survival than those treated with standard care therapy alone.

SECONDARY OBJECTIVES:

I. To evaluate response rate. II. To assess toxicity. III. To assess overall survival. IV. To correlate clinical outcomes with tumor molecular aberrations identified from deep sequencing of selected kinomes in patients from whom adequate baseline tissue is available.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I (induction therapy): Patients receive erlotinib hydrochloride orally (PO) once daily (QD) for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.

ARM III (induction therapy): Patients receive crizotinib PO twice daily (BID) for up to 12 weeks. Patients who have had no response (partial or complete) after 6 weeks undergo concurrent chemoradiation therapy immediately. After 2 weeks of completion of induction therapy, patients receive chemoradiation.

ARMS II AND IV (concurrent chemoradiation): Patients receive concurrent chemotherapy with thoracic radiation therapy beginning on day 1. Treatment continues in the absence of disease progression or unacceptable toxicity.

CHEMORADIATION: In all treatment arms, patients undergo concurrent intensity modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3-D CRT) QD 5 days a week for 6 weeks. Patients receive 1 of 2 chemotherapy regimens based on the discretion of the treating physician. Patients receive cisplatin intravenously (IV) over 1-2 hours on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Treatment repeats every 4 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Some patients receive paclitaxel IV and carboplatin IV on days 1, 8, 15, 22, 29, and 36 during radiation therapy for 6 weeks. Two courses of consolidation treatment will begin 4-6 weeks after completion of radiation therapy with paclitaxel IV on days 1 and 22 and carboplatin IV on days 1 and 22 in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 2 months, 4-6 weeks, every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed, newly diagnosed non-squamous NSCLC
  • Unresectable stage IIIA or IIIB disease; patients must be surgically staged to confirm N2 or N3 disease; patients may have invasive mediastinal staging by mediastinoscopy, mediastinotomy, endobronchial ultrasound transbronchial aspiration (EBUS-TBNA), endoscopic ultrasound (EUS), or video-assisted thoracoscopic surgery (VATS)
  • Patients with any tumor (T) with node (N)2 or N3 are eligible; patients with T3, N1-N3 disease are eligible if deemed unresectable; patients with T4, any N are eligible
  • Patients must have measurable disease, i.e., lesions that can be accurately measured in at least 1 dimension (longest dimension in the plane of measurement is to be recorded) with a minimum size of 10 mm by computed tomography (CT) scan (CT scan slice thickness no greater than 5 mm)
  • Patients with a pleural effusion, which is a transudate, cytologically negative and non-bloody, are eligible if the radiation oncologist feels the tumor can be encompassed within a reasonable field of radiotherapy
  • If a pleural effusion can be seen on the chest CT but not on chest x-ray and is too small to tap, the patient will be eligible; patients who develop a new pleural effusion after thoracotomy or other invasive thoracic procedure will be eligible
  • The institution's pre-enrollment biomarker screening at a Clinical Laboratory Improvement Amendments (CLIA) certified lab documents presence of known "sensitive" mutations in epidermal growth factor receptor tyrosine kinase (EGFR TK) domain (exon 19 deletion, L858) and/or EML4-anaplastic lymphoma kinase (ALK) fusion arrangement; either the primary tumor or the metastatic lymph node tissue may be used for testing of mutations
  • The institution's pre-enrollment biomarker screening at a CLIA certified lab documents absence of T790M mutation in the EGFR TK domain
  • Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:

    • History/physical examination, including recording of pulse, blood pressure (BP), weight, and body surface area, within 45 days prior to registration
    • Whole body fludeoxyglucose-positron emission tomography (FDG-PET)/CT (orbits to mid-thighs) within 30 days prior to registration; PET/CT must be negative for distant metastasis
    • CT scan with contrast of the chest and upper abdomen to include liver and adrenals (unless medically contraindicated) within 30 days prior to registration
    • Magnetic resonance imaging (MRI) of the brain with contrast (or CT scan with contrast, if MRI medically contraindicated) within 30 days prior to registration
  • Zubrod performance status 0-1 within 14 days prior to registration
  • Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
  • Platelets >= 100,000 cells/mm^3
  • Hemoglobin >= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin [Hgb] >= 8.0 g/dl is acceptable)
  • Serum creatinine < 1.5 mg/dL or calculated creatinine clearance >= 50 ml/min (by Cockcroft-Gault formula) within 14 days prior to registration
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) within 14 days prior to registration
  • Bilirubin within normal institutional limits within 14 days prior to registration
  • Negative serum pregnancy test within 14 days prior to registration for women of childbearing potential
  • Patient must provide study specific informed consent prior to study entry, including consent for mandatory screening of tissue

Exclusion Criteria:

  • Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 730 days (2 years) (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
  • Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • Atelectasis of the entire lung
  • Contralateral hilar node involvement
  • Exudative, bloody, or cytologically malignant effusions
  • Severe, active co-morbidity, defined as follows:

    • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
    • Transmural myocardial infarction within the last 6 months
    • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
    • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration; hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
    • Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol; protocol-specific requirements may also exclude immuno-compromised patients
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
  • Prior allergic reaction to the study drug(s) involved in this protocol
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01822496


  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Cancer Center Suspended
Birmingham, Alabama, United States, 35233
United States, Alaska
Providence Alaska Medical Center Recruiting
Anchorage, Alaska, United States, 99508
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Daniel D. Chamberlain    602-747-9738      
Principal Investigator: Daniel D. Chamberlain         
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: Yolanda I. Garces    855-776-0015      
Principal Investigator: Yolanda I. Garces         
United States, California
AIS Cancer Center at San Joaquin Community Hospital Recruiting
Bakersfield, California, United States, 93301
Contact: Megan E. Daly    916-734-3089      
Principal Investigator: Megan E. Daly         
UC San Diego Moores Cancer Center Suspended
La Jolla, California, United States, 92093
Fremont - Rideout Cancer Center Recruiting
Marysville, California, United States, 95901
Contact: Megan E. Daly    916-734-3089      
Principal Investigator: Megan E. Daly         
Mercy UC Davis Cancer Center Recruiting
Merced, California, United States, 95340
Contact: Parminder S. Sidhu    916-734-3089      
Principal Investigator: Parminder S. Sidhu         
Stanford Cancer Institute Palo Alto Suspended
Palo Alto, California, United States, 94304
University of California Davis Comprehensive Cancer Center Recruiting
Sacramento, California, United States, 95817
Contact: Megan E. Daly    916-734-3089      
Principal Investigator: Megan E. Daly         
Saint Helena Hospital Active, not recruiting
Saint Helena, California, United States, 94574
UCSF Medical Center-Mount Zion Suspended
San Francisco, California, United States, 94115
Gene Upshaw Memorial Tahoe Forest Cancer Center Recruiting
Truckee, California, United States, 96161
Contact: Megan E. Daly    916-734-3089      
Principal Investigator: Megan E. Daly         
United States, Colorado
University of Colorado Hospital Recruiting
Aurora, Colorado, United States, 80045
Contact: Brian D. Kavanagh    720-848-0650      
Principal Investigator: Brian D. Kavanagh         
Rocky Mountain Cancer Centers-Boulder Recruiting
Boulder, Colorado, United States, 80304
Contact: Keren Sturtz    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Mehmet S. Copur    501-622-2100      
Principal Investigator: Mehmet S. Copur         
Memorial Hospital Central Recruiting
Colorado Springs, Colorado, United States, 80909
Contact: Jane W. Ridings    719-365-2406      
Principal Investigator: Jane W. Ridings         
Poudre Valley Hospital Recruiting
Fort Collins, Colorado, United States, 80524
Contact: Brian D. Kavanagh    720-848-0650      
Principal Investigator: Brian D. Kavanagh         
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Keren Sturtz    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Keren Sturtz    303-777-2663    ccrp@co-cancerresearch.org   
Principal Investigator: Keren Sturtz         
United States, Connecticut
Hartford Hospital Suspended
Hartford, Connecticut, United States, 06102
The Hospital of Central Connecticut Suspended
New Britain, Connecticut, United States, 06050
United States, Delaware
Christiana Care Health System-Christiana Hospital Recruiting
Newark, Delaware, United States, 19718
Contact: Adam Raben    302-733-6227      
Principal Investigator: Adam Raben         
United States, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Recruiting
Deerfield Beach, Florida, United States, 33442
Contact: Adrian S. Ishkanian    305-243-2647      
Principal Investigator: Adrian S. Ishkanian         
Memorial Regional Hospital/Joe DiMaggio Children's Hospital Suspended
Hollywood, Florida, United States, 33021
Baptist MD Anderson Cancer Center Recruiting
Jacksonville, Florida, United States, 32207
Contact: Mark E. Augspurger    904-202-7051      
Principal Investigator: Mark E. Augspurger         
Baptist Medical Center South Suspended
Jacksonville, Florida, United States, 32258
University of Miami Miller School of Medicine-Sylvester Cancer Center Recruiting
Miami, Florida, United States, 33136
Contact: Adrian S. Ishkanian    305-243-2647      
Principal Investigator: Adrian S. Ishkanian         
UF Cancer Center at Orlando Health Recruiting
Orlando, Florida, United States, 32806
Contact: Justin Rineer    321-841-7246    CancerClinicalTrials@orlandohealth.com   
Principal Investigator: Justin Rineer         
21st Century Oncology-Palatka Suspended
Palatka, Florida, United States, 32177
Memorial Hospital West Suspended
Pembroke Pines, Florida, United States, 33028
Integrated Community Oncology Network-Flager Cancer Center Suspended
Saint Augustine, Florida, United States, 32086
Robert and Carol Weissman Cancer Center at Martin Health Suspended
Stuart, Florida, United States, 34994
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Thomas J. Dilling    800-456-7121    canceranswers@moffitt.org   
Principal Investigator: Thomas J. Dilling         
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Kristin A. Higgins    404-778-1868      
Principal Investigator: Kristin A. Higgins         
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Kristin A. Higgins    404-778-1868      
Principal Investigator: Kristin A. Higgins         
Emory Saint Joseph's Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Kristin A. Higgins    404-778-1868      
Principal Investigator: Kristin A. Higgins         
Northeast Georgia Medical Center-Gainesville Suspended
Gainesville, Georgia, United States, 30501
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler Recruiting
Savannah, Georgia, United States, 31405
Contact: John A. Pablo    912-819-5704      
Principal Investigator: John A. Pablo         
United States, Hawaii
Queen's Medical Center Suspended
Honolulu, Hawaii, United States, 96813
The Cancer Center of Hawaii-Liliha Suspended
Honolulu, Hawaii, United States, 96817
United States, Idaho
Saint Alphonsus Cancer Care Center-Boise Recruiting
Boise, Idaho, United States, 83706
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Nisha A. Mohindra    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Nisha A. Mohindra         
University of Illinois Suspended
Chicago, Illinois, United States, 60612
University of Chicago Comprehensive Cancer Center Suspended
Chicago, Illinois, United States, 60637
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
Crossroads Cancer Center Recruiting
Effingham, Illinois, United States, 62401
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
AMITA Health Alexian Brothers Medical Center Recruiting
Elk Grove Village, Illinois, United States, 60007
Contact: Martin J. Boyer    847-952-7164    fredianc@alexian.net   
Principal Investigator: Martin J. Boyer         
Elmhurst Memorial Hospital Active, not recruiting
Elmhurst, Illinois, United States, 60126
AMITA Health Cancer Institute and Outpatient Center Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Kapila Kalakota    630-286-5500      
Principal Investigator: Kapila Kalakota         
Loyola University Medical Center Suspended
Maywood, Illinois, United States, 60153
Edward Hospital/Cancer Center Active, not recruiting
Naperville, Illinois, United States, 60540
Edward Hospital/Cancer Center?Plainfield Active, not recruiting
Plainfield, Illinois, United States, 60585
SwedishAmerican Regional Cancer Center/ACT Recruiting
Rockford, Illinois, United States, 61114
Contact: Harvey E. Einhorn    779-696-9400    cancercare@swedishamerican.org   
Principal Investigator: Harvey E. Einhorn         
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
United States, Indiana
Saint Vincent Anderson Regional Hospital/Cancer Center Recruiting
Anderson, Indiana, United States, 46016
Contact: Alexander M. Yeh    765-646-8358      
Principal Investigator: Alexander M. Yeh         
Radiation Oncology Associates PC Recruiting
Fort Wayne, Indiana, United States, 46804
Contact: Brian K. Chang    260-373-8888    parkviewresearch@parkview.com   
Principal Investigator: Brian K. Chang         
Parkview Hospital Randallia Recruiting
Fort Wayne, Indiana, United States, 46805
Contact: Brian K. Chang    260-373-8888    parkviewresearch@parkview.com   
Principal Investigator: Brian K. Chang         
United States, Iowa
McFarland Clinic PC-William R Bliss Cancer Center Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Saint Luke's Hospital Recruiting
Cedar Rapids, Iowa, United States, 52402
Contact: Nagendra (Bobby) S. Koneru    800-397-2467      
Principal Investigator: Nagendra (Bobby) S. Koneru         
Mercy Hospital Suspended
Cedar Rapids, Iowa, United States, 52403
Siouxland Regional Cancer Center Suspended
Sioux City, Iowa, United States, 51101
United States, Maine
Harold Alfond Center for Cancer Care Suspended
Augusta, Maine, United States, 04330
Maine Medical Center- Scarborough Campus Recruiting
Scarborough, Maine, United States, 04074
Contact: Matthew D. Cheney    207-396-8090    wrighd@mmc.org   
Principal Investigator: Matthew D. Cheney         
United States, Maryland
University of Maryland/Greenebaum Cancer Center Recruiting
Baltimore, Maryland, United States, 21201
Contact: Pranshu Mohindra    800-888-8823      
Principal Investigator: Pranshu Mohindra         
Sinai Hospital of Baltimore Suspended
Baltimore, Maryland, United States, 21215
United States, Massachusetts
Tufts Medical Center Active, not recruiting
Boston, Massachusetts, United States, 02111
Beth Israel Deaconess Medical Center Suspended
Boston, Massachusetts, United States, 02215
Dana-Farber Cancer Institute Suspended
Boston, Massachusetts, United States, 02215
Lahey Hospital and Medical Center Recruiting
Burlington, Massachusetts, United States, 01805
Contact: Krishna S. Gunturu    781-744-8027      
Principal Investigator: Krishna S. Gunturu         
Lowell General Hospital Suspended
Lowell, Massachusetts, United States, 01854
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
Beaumont Hospital-Dearborn Recruiting
Dearborn, Michigan, United States, 48124
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
Mercy Health Saint Mary's Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Kathleen J. Yost    616-391-1230    crcwm-regulatory@crcwm.org   
Principal Investigator: Kathleen J. Yost         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Samir Narayan    208-367-7954      
Principal Investigator: Samir Narayan         
United States, Minnesota
Mercy Hospital Recruiting
Coon Rapids, Minnesota, United States, 55433
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Miller-Dwan Hospital Recruiting
Duluth, Minnesota, United States, 55805
Contact: Bret E. Friday    888-203-7267      
Principal Investigator: Bret E. Friday         
Unity Hospital Recruiting
Fridley, Minnesota, United States, 55432
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Abbott-Northwestern Hospital Recruiting
Minneapolis, Minnesota, United States, 55407
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Hennepin County Medical Center Recruiting
Minneapolis, Minnesota, United States, 55415
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Yolanda I. Garces    855-776-0015      
Principal Investigator: Yolanda I. Garces         
Park Nicollet Clinic - Saint Louis Park Recruiting
Saint Louis Park, Minnesota, United States, 55416
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Regions Hospital Recruiting
Saint Paul, Minnesota, United States, 55101
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
United Hospital Recruiting
Saint Paul, Minnesota, United States, 55102
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
Rice Memorial Hospital Recruiting
Willmar, Minnesota, United States, 56201
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
United States, Missouri
Southeast Cancer Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
Siteman Cancer Center at West County Hospital Recruiting
Creve Coeur, Missouri, United States, 63141
Contact: Ramaswamy Govindan    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Ramaswamy Govindan         
Saint Luke's Hospital of Kansas City Suspended
Kansas City, Missouri, United States, 64111
Delbert Day Cancer Institute at PCRMC Recruiting
Rolla, Missouri, United States, 65401
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Ramaswamy Govindan    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Ramaswamy Govindan         
Missouri Baptist Medical Center Recruiting
Saint Louis, Missouri, United States, 63131
Contact: James L. Wade    309-243-3605      
Principal Investigator: James L. Wade         
Mercy Hospital Saint Louis Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
CoxHealth South Hospital Recruiting
Springfield, Missouri, United States, 65807
Contact: Jay W. Carlson    888-221-4849      
Principal Investigator: Jay W. Carlson         
United States, Nebraska
Nebraska Methodist Hospital Recruiting
Omaha, Nebraska, United States, 68114
Contact: Tien-Shew W. Huang    402-354-5144      
Principal Investigator: Tien-Shew W. Huang         
United States, New Hampshire
Concord Hospital Recruiting
Concord, New Hampshire, United States, 03301
Contact: Bryan P. Rowe    603-663-1800      
Principal Investigator: Bryan P. Rowe         
Elliot Hospital Recruiting
Manchester, New Hampshire, United States, 03103
Contact: Brian Knab    603-663-1800      
Principal Investigator: Brian Knab         
United States, New Jersey
Virtua Memorial Recruiting
Mount Holly, New Jersey, United States, 08060
Contact: Lemuel S. Ariaratnam    609-914-6762      
Principal Investigator: Lemuel S. Ariaratnam         
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Suspended
New Brunswick, New Jersey, United States, 08903
Rutgers Cancer Institute of New Jersey Recruiting
New Brunswick, New Jersey, United States, 08903
Contact: Salma K. Jabbour    732-235-8675      
Principal Investigator: Salma K. Jabbour         
Community Medical Center Recruiting
Toms River, New Jersey, United States, 08755
Contact: David J. D'Ambrosio    732-818-3882      
Principal Investigator: David J. D'Ambrosio         
Virtua Voorhees Recruiting
Voorhees, New Jersey, United States, 08043
Contact: Lemuel S. Ariaratnam    609-914-6762      
Principal Investigator: Lemuel S. Ariaratnam         
United States, New Mexico
University of New Mexico Cancer Center Recruiting
Albuquerque, New Mexico, United States, 87102
Contact: Thomas M. Schroeder    505-925-0366    LByatt@nmcca.org   
Principal Investigator: Thomas M. Schroeder         
United States, New York
Mary Imogene Bassett Hospital Recruiting
Cooperstown, New York, United States, 13326
Contact: Joy E. Anderson    607-547-3073    diana.crean@bassett.org   
Principal Investigator: Joy E. Anderson         
Beth Israel Medical Center Suspended
New York, New York, United States, 10003
Mount Sinai Hospital Suspended
New York, New York, United States, 10029
Weill Medical College of Cornell University Suspended
New York, New York, United States, 10065
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Yuhchyau Chen    585-341-8113      
Principal Investigator: Yuhchyau Chen         
Staten Island University Hospital Recruiting
Staten Island, New York, United States, 10305
Contact: Alexander Bershadskiy    718-226-8888      
Principal Investigator: Alexander Bershadskiy         
State University of New York Upstate Medical University Suspended
Syracuse, New York, United States, 13210
United States, North Carolina
Cancer Care of Western North Carolina Suspended
Asheville, North Carolina, United States, 28801
Mission Hospital-Memorial Campus Suspended
Asheville, North Carolina, United States, 28801
FirstHealth of the Carolinas-Moore Regional Hosiptal Recruiting
Pinehurst, North Carolina, United States, 28374
Contact: Charles S. Kuzma    619-532-8712      
Principal Investigator: Charles S. Kuzma         
Wake Forest University Health Sciences Suspended
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Summa Akron City Hospital/Cooper Cancer Center Recruiting
Akron, Ohio, United States, 44304
Contact: Desiree E. Doncals    330-615-4132      
Principal Investigator: Desiree E. Doncals         
Akron General Medical Center Recruiting
Akron, Ohio, United States, 44307
Contact: Mitchel L. Fromm    330-344-6348      
Principal Investigator: Mitchel L. Fromm         
Summa Barberton Hospital Recruiting
Barberton, Ohio, United States, 44203
Contact: Desiree E. Doncals    330-615-4132      
Principal Investigator: Desiree E. Doncals         
Adena Regional Medical Center Recruiting
Chillicothe, Ohio, United States, 45601
Contact: Timothy D. Moore    614-488-2745    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Case Western Reserve University Suspended
Cleveland, Ohio, United States, 44106
Cleveland Clinic Cancer Center/Fairview Hospital Suspended
Cleveland, Ohio, United States, 44111
Cleveland Clinic Foundation Suspended
Cleveland, Ohio, United States, 44195
Ohio State University Comprehensive Cancer Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Meng X. Welliver    800-293-5066    Jamesline@osumc.edu   
Principal Investigator: Meng X. Welliver         
Grant Medical Center Recruiting
Columbus, Ohio, United States, 43215
Contact: Timothy D. Moore    614-488-2745    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
The Mark H Zangmeister Center Recruiting
Columbus, Ohio, United States, 43219
Contact: Timothy D. Moore    614-488-2745    sheree@columbusccop.org   
Principal Investigator: Timothy D. Moore         
Mercy Cancer Center-Elyria Suspended
Elyria, Ohio, United States, 44035
Cleveland Clinic Cancer Center Independence Suspended
Independence, Ohio, United States, 44131
North Coast Cancer Care Suspended
Sandusky, Ohio, United States, 44870
Cleveland Clinic Cancer Center Strongsville Suspended
Strongsville, Ohio, United States, 44136
Cleveland Clinic Wooster Family Health and Surgery Center Suspended
Wooster, Ohio, United States, 44691
United States, Oklahoma
University of Oklahoma Health Sciences Center Suspended
Oklahoma City, Oklahoma, United States, 73104
Natalie Warren Bryant Cancer Center at Saint Francis Suspended
Tulsa, Oklahoma, United States, 74136
United States, Oregon
Clackamas Radiation Oncology Center Recruiting
Clackamas, Oregon, United States, 97015
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
Legacy Mount Hood Medical Center Active, not recruiting
Gresham, Oregon, United States, 97030
Legacy Good Samaritan Hospital and Medical Center Active, not recruiting
Portland, Oregon, United States, 97210
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
Kaiser Permanente Northwest Recruiting
Portland, Oregon, United States, 97227
Contact: Sandeep H. Mashru    503-335-2400      
Principal Investigator: Sandeep H. Mashru         
Salem Hospital Suspended
Salem, Oregon, United States, 97301
United States, Pennsylvania
Bryn Mawr Hospital Recruiting
Bryn Mawr, Pennsylvania, United States, 19010
Contact: Albert S. DeNittis    484-476-2649    ewend@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822
Contact: Fiori Alite    570-271-5251      
Principal Investigator: Fiori Alite         
Paoli Memorial Hospital Recruiting
Paoli, Pennsylvania, United States, 19301
Contact: Albert S. DeNittis    484-476-2649    ewend@mlhs.org   
Principal Investigator: Albert S. DeNittis         
Fox Chase Cancer Center Suspended
Philadelphia, Pennsylvania, United States, 19111
Guthrie Medical Group PC-Robert Packer Hospital Suspended
Sayre, Pennsylvania, United States, 18840
Lankenau Medical Center Recruiting
Wynnewood, Pennsylvania, United States, 19096
Contact: Albert S. DeNittis    484-476-2649    ewend@mlhs.org   
Principal Investigator: Albert S. DeNittis         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Carol A. Sherman    843-792-9321      
Principal Investigator: Carol A. Sherman         
Greenville Health System Cancer Institute-Faris Recruiting
Greenville, South Carolina, United States, 29605
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Greenville Health System Cancer Institute-Eastside Recruiting
Greenville, South Carolina, United States, 29615
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Self Regional Healthcare Recruiting
Greenwood, South Carolina, United States, 29646
Contact: Joanna K. Metzner-Sadurski    864-725-4771      
Principal Investigator: Joanna K. Metzner-Sadurski         
Greenville Health System Cancer Institute-Greer Recruiting
Greer, South Carolina, United States, 29650
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Gibbs Cancer Center-Pelham Recruiting
Greer, South Carolina, United States, 29651
Contact: Patricia C. Griffin    412-339-5294    Roster@nrgoncology.org   
Principal Investigator: Patricia C. Griffin         
Greenville Health System Cancer Institute-Seneca Recruiting
Seneca, South Carolina, United States, 29672
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Patricia C. Griffin    800-486-5941      
Principal Investigator: Patricia C. Griffin         
Greenville Health System Cancer Institute-Spartanburg Recruiting
Spartanburg, South Carolina, United States, 29307
Contact: David L. Grisell    864-679-3966      
Principal Investigator: David L. Grisell         
United States, Texas
The Don and Sybil Harrington Cancer Center Recruiting
Amarillo, Texas, United States, 79106
Contact: Daniel Arsenault    806-212-1985    gcravey@harringtoncc.org   
Principal Investigator: Daniel Arsenault         
UT Southwestern/Simmons Cancer Center-Dallas Recruiting
Dallas, Texas, United States, 75390
Contact: Hak Choy    214-590-5582      
Principal Investigator: Hak Choy         
M D Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Anne S. Tsao    713-792-3245      
Principal Investigator: Anne S. Tsao         
Covenant Medical Center-Lakeside Suspended
Lubbock, Texas, United States, 79410
United States, Utah
Intermountain Medical Center Recruiting
Murray, Utah, United States, 84107
Contact: George M. Cannon    801-408-1347      
Principal Investigator: George M. Cannon         
Dixie Medical Center Regional Cancer Center Recruiting
Saint George, Utah, United States, 84770
Contact: George M. Cannon    801-408-1347      
Principal Investigator: George M. Cannon         
United States, Washington
PeaceHealth Saint John Medical Center Recruiting
Longview, Washington, United States, 98632
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
PeaceHealth Southwest Medical Center Recruiting
Vancouver, Washington, United States, 98664
Contact: Benjamin B. Bridges    907-212-6871    AKPAMC.OncologyResearchSupport@providence.org   
Principal Investigator: Benjamin B. Bridges         
United States, West Virginia
Edwards Comprehensive Cancer Center Suspended
Huntington, West Virginia, United States, 25701
United States, Wisconsin
Saint Vincent Hospital Cancer Center Green Bay Suspended
Green Bay, Wisconsin, United States, 54301
Saint Vincent Hospital Cancer Center at Saint Mary's Suspended
Green Bay, Wisconsin, United States, 54303
Community Memorial Hospital Suspended
Menomonee Falls, Wisconsin, United States, 53051
Columbia Saint Mary's Hospital - Ozaukee Suspended
Mequon, Wisconsin, United States, 53097
Columbia Saint Mary's Water Tower Medical Commons Suspended
Milwaukee, Wisconsin, United States, 53211
Froedtert and the Medical College of Wisconsin Suspended
Milwaukee, Wisconsin, United States, 53226
Cancer Center of Western Wisconsin Recruiting
New Richmond, Wisconsin, United States, 54017
Contact: Paul W. Sperduto    952-993-1517    mmcorc@healthpartners.com   
Principal Investigator: Paul W. Sperduto         
ProHealth Waukesha Memorial Hospital Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Wingate F. Clapper    262-928-7632      
Principal Investigator: Wingate F. Clapper         
The Alyce and Elmore Kraemer Cancer Care Center Suspended
West Bend, Wisconsin, United States, 53095
Sponsors and Collaborators
National Cancer Institute (NCI)
Investigators
Principal Investigator: Ramaswamy Govindan NRG Oncology
  More Information

Responsible Party: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT01822496     History of Changes
Other Study ID Numbers: NCI-2013-00737
NCI-2013-00737 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
RTOG-1306 ( Other Identifier: NRG Oncology )
RTOG-1306 ( Other Identifier: CTEP )
U10CA180868 ( U.S. NIH Grant/Contract )
U10CA021661 ( U.S. NIH Grant/Contract )
First Submitted: April 1, 2013
First Posted: April 2, 2013
Last Update Posted: December 8, 2017
Last Verified: November 2017

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Etoposide phosphate
Carboplatin
Erlotinib Hydrochloride
Etoposide
Paclitaxel
Cisplatin
Podophyllotoxin
Crizotinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Keratolytic Agents
Dermatologic Agents